Dr. Tice is internationally recognized for his research and product development of complex parenteral, various drug delivery dosage forms based on bioabsorbable polymer excipients. He is known for his accomplishments years involving long-acting injectable microparticles made with bioabsorbable lactide/glycolide polymers designed for systemic and local drug delivery. He was a team leader and core inventor to develop the first commercial, injectable, extended-release microparticle product. This product, a one-month LHRH formulation indicated for the treatment of prostate cancer (Decapeptyl® SR), is still on the market today. He has also served on various US Pharmacopeia expert committees for 17 years, and is currently on the General Chapters Dosage Forms Expert Committee and Excipient Joint Committee. He currently serves on the Board of McWhorter School of Pharmacy at Samford University. At Evonik, Dr. Tice, provides scientific support to Evonik’s innovation, sales, product development, research, intellectual property and M&A teams. He earned his BSc in Chemistry and PhD in Biophysics from Syracuse University, New York. He held a postdoctoral fellow position at the University of Alabama at Birmingham (UAB) in Microbiology. He holds 48 US patents with many foreign equivalents and has more than 225 publications, presentations, and invited lectures to his credit. He has 45 years of experience with long-acting injectables and lactide/glycolide polymers. He flew experiments on two Space Shuttle flights.See my inspirational note “Inspirational Chemistry of Bioabsorbable Long-Acting Injectables”.